Table 2.
Comparison of characteristics on arterial phase at Sonovue and Sonazoid-enhanced ultrasound.
| Variable | Nonrim APHE | Rim APHE | Peripheral Globular Enhancement |
No APHE | ||||
|---|---|---|---|---|---|---|---|---|
| Sonovue | Sonazoid | Sonovue | Sonazoid | Sonovue | Sonazoid | Sonovue | Sonazoid | |
| HCC (n=55) | 54 (98.2) | 54 ((98.2) | 1 (1.8) | 1 (1.8) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Non-HCC malignancy (n=3) | 2 (66.7) | 1 (33.3) | 1 (33.3) | 2 (66.7) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Benign lesions (n=4) | 0 (0) | 1(25) | 1 (25) | 1(25) | 2 (50) | 2(50) | 1 (25) | 0 (0) |
Data are numbers of nodules with percentage in parentheses. APHE, arterial phase hyperenhancement; HCC, hepatocellular carcinoma.